Clinical Radiology
Volume 64, Issue 6 , Pages 589-600 , June 2009

Radiological evaluation, management, and surveillance of renal masses in Von Hippel–Lindau disease

  • M. Meister

      Affiliations

    • Department of Radiology, St Georges Hospital, London
    • ,
  • P. Choyke

      Affiliations

    • Department of Radiology, National Institute of Health, Bethesda, Maryland, USA
    • ,
  • C. Anderson

      Affiliations

    • Department of Urology, St Georges Hospital, London
    • ,
  • U. Patel

      Affiliations

    • Department of Radiology, St Georges Hospital, London
    • Corresponding Author InformationGuarantor and correspondent: U. Patel, Department of Radiology, St George's Hospital, Blackshaw Road, London, SW17 0QT, UK.

Received 11 June 2008 ,Revised 8 October 2008 ,Accepted 26 October 2008.

References 

  1. Richard S, Graff J, Llndau J, Resche F. Von Hippel–Lindau disease. Lancet. 2004;363:1231–1234
  2. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel–Lindau disease tumor suppressor gene. Science. 1993;260:1317–1320
  3. Maher ER. Von Hippel–Lindau disease. Curr Mol Med. 2004;4:833–842
  4. Pavlovich CP, Schmidt LS. Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer. 2004;4:381–393
  5. Banks RE, Tirukonda P, Taylor C, et al. Genetic and epigenetic analysis of von Hippel–Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res. 2006;66:2000–2011
  6. http://info.cancerresearchuk.org/cancerstats/types/kidney/incidence/. (accessed 12 January 2008)
  7. Chow WH, Devesa SS, Warren JL, Fraumeni JF. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281:1628–1631
  8. Patard JJ, Rodriguez A, Rioux-Leclercq N, et al. Prognostic significance of the mode of detection in renal tumours. BJU Int. 2002;90:358–363
  9. Tsui KH, Shvarts O, Smith RB, et al. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol. 2000;163:426–430
  10. Choyke PL, Glenn GM, Walther MM, et al. Hereditary renal cancers. Radiology. 2003;226:33–46
  11. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003;170:2163–2172
  12. Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2006;118:728–738
  13. Ong KR, Woodward ER, Killick P, et al. Genotype–phenotype correlations in von Hippel–Lindau disease. Hum Mutat. 2007;28:143–149
  14. Hes FJ, Feldberg MA. Von Hippel–Lindau disease: strategies in early detection (renal-, adrenal-, pancreatic masses). Eur Radiol. 1999;9:598–610
  15. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820–823
  16. Zbar B, Kishida T, Chen F, et al. Germline mutations in the Von Hippel–Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat. 1996;8:348–357
  17. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22:4991–5004
  18. Lonser RR, Glenn GM, Walther M, et al. von Hippel–Lindau disease. Lancet. 2003;361:2059–2067
  19. Poston CD, Jaffe GS, Lubensky IA, et al. Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel–Lindau disease: clinical and molecular genetic implications. J Urol. 1995;153:22–26
  20. Walther MM, Lubensky IA, Venzon D, et al. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel–Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J Urol. 1995;154:2010–2014discussion 2014–5
  21. Neumann HP, Bender BU, Berger DP, et al. Prevalence, morphology and biology of renal cell carcinoma in von Hippel–Lindau disease compared to sporadic renal cell carcinoma. J Urol. 1998;160:1248–1254
  22. Maher ER, YAtes JR, Harries R, et al. Clinical features and natural history of von Hippel–Lindau disease. Q J Med. 1990;77:1151–1163
  23. Choyke PL, Glenn GM, Walther MM, et al. von Hippel–Lindau disease: genetic, clinical, and imaging features. Radiology. 1995;194:629–642
  24. Leung RS, Biswas SV, Duncan M, Rankin S. Imaging features of von Hippel–Lindau disease. RadioGraphics. 2008;28:65–79quiz 323
  25. Bosniak MA. The current radiological approach to renal cysts. Radiology. 1986;158:1–10
  26. Israel GM, Hindman N, Bosniak MA. Evaluation of cystic renal masses: comparison of CT and MR imaging by using the Bosniak classification system. Radiology. 2004;231:365–371
  27. Israel GM, Bosniak MA. Follow-up CT of moderately complex cystic lesions of the kidney (Bosniak category IIF). AJR Am J Roentgenol. 2003;181:627–633
  28. Curry NS, Cochran ST, Bissada NK. Cystic renal masses: accurate Bosniak classification requires adequate renal CT. AJR Am J Roentgenol. 2000;175:339–342
  29. Harisinghani MG, Maher MM, Gervais DA, et al. Incidence of malignancy in complex cystic renal masses (Bosniak category III): should imaging-guided biopsy precede surgery?. AJR Am J Roentgenol. 2003;180:755–758
  30. Bosniak MA. Should we biopsy complex cystic renal masses (Bosniak category III)?. AJR Am J Roentgenol. 2003;181:1425–1426author reply 1426
  31. Israel GM, Bosniak MA. How I do it: evaluating renal masses. Radiology. 2005;236:441–450
  32. Claudon M, Cosgrove D, Albrecht T, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) — update 2008. Ultraschall Med. 2008;29:28–44
  33. Ascenti G, Mazzioti S, Zimbaro G, et al. Complex cystic renal masses: characterization with contrast-enhanced US. Radiology. 2007;243:158–165
  34. Cohan RH, Sherman LS, Korbkin M, et al. Renal masses: assessment of corticomedullary-phase and nephrographic-phase CT scans. Radiology. 1995;196:445–451
  35. Beer AJ, Dobritz M, Zantl N, et al. Comparison of 16-MDCT and MRI for characterization of kidney lesions. AJR Am J Roentgenol. 2006;186:1639–1650
  36. Tattersall DJ, Moore NR. von Hippel–Lindau disease: MRI of abdominal manifestations. Clin Radiol. 2002;57:85–92
  37. Semelka RC, Cumming MJ, Shoenut JP, et al. Islet cell tumors: comparison of dynamic contrast-enhanced CT and MR imaging with dynamic gadolinium enhancement and fat suppression. Radiology. 1993;186:799–802
  38. Lauenstein TC, Salman K, Morreira R, et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging. 2007;26:1198–1203
  39. Walter C, Kruessell M, Gindele A, et al. Imaging of renal lesions: evaluation of fast MRI and helical CT. Br J Radiol. 2003;76:696–703
  40. Walther MM, Choyke PL, Glenn G, et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol. 1999;161:1475–1479
  41. Richard S. von Hippel–Lindau disease: recent advances and therapeutic perspectives. Expert Rev Anticancer Ther. 2003;3:215–233
  42. Grubb RL, Choyke PL, Pinto PA, et al. Management of von Hippel–Lindau-associated kidney cancer. Nat Clin Pract Urol. 2005;2:248–255
  43. Duffey BG, Choyke PL, Glenn G, et al. The relationship between renal tumor size and metastases in patients with von Hippel–Lindau disease. J Urol. 2004;172:63–65
  44. Goldfarb DA, Neumann HP, Penn I, Novick AC. Results of renal transplantation in patients with renal cell carcinoma and von Hippel–Lindau disease. Transplantation. 1997;64:1726–1729
  45. Choyke PL, Daryanani K. Intraoperative ultrasound of the kidney. Ultrasound Q. 2001;17:245–253
  46. Herring JC, Enquist EG, Chernoff A, et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol. 2001;165:777–781
  47. Shingleton WB, Sewell PE. Percutaneous renal cryoablation of renal tumors in patients with von Hippel–Lindau disease. J Urol. 2002;167:1268–1270
  48. Gervais DA, McGovern FJ, Arellano RS, et al. Renal cell carcinoma: clinical experience and technical success with radio-frequency ablation of 42 tumors. Radiology. 2003;226:417–424
  49. Su LM, Jarrett TW, Chan DY, et al. Percutaneous computed tomography-guided radiofrequency ablation of renal masses in high surgical risk patients: preliminary results. Urology. 2003;61(Suppl. 1):26–33
  50. Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002;2:673–682
  51. Richards RD, Mebust WK, Schimke RN. A prospective study on Von Hippel–Lindau disease. J Urol. 1973;110:27–30
  52. Lee KR, Wulfsberg E, Kepes JJ. Some important radiological aspects of the kidney in von Hippel–Lindau syndrome: the value of prospective study in an affected family. Radiology. 1977;122:649–653
  53. Filling-Katz MR, et al. Radiologic screening for von Hippel–Lindau disease: the role of Gd-DTPA enhanced MR imaging of the CNS. J Comput Assist Tomogr. 1989;13:743–755

PII: S0009-9260(08)00442-X

doi: 10.1016/j.crad.2008.10.010

Clinical Radiology
Volume 64, Issue 6 , Pages 589-600 , June 2009

Article Tools

* Image Usage & Resolution